Download PDF
TumorDiagnostik & Therapie 2018; 39(04): 235-238
DOI: 10.1055/a-0583-8857
Schwerpunkt Lymphome
© Georg Thieme Verlag KG Stuttgart · New York

Multiples Myelom – Update 2018

Martin Kortüm
,
Hermann Einsele
Further Information

Publication History

Publication Date:
14 May 2018 (online)

Also available at
    Permissions and Reprints

Das Multiple Myelom ist eines der dynamischsten Felder in der gesamten Krebsmedizin. Auch auf dem Kongress der Amerikanischen Hämatologischen Gesellschaft (ASH) in Atlanta betrafen wieder mehrere hundert Einreichungen das Multiple Myelom. Dieser Beitrag fasst den gegenwärtigen Stand der Diagnostik und der Therapie zusammen und gibt einen Ausblick auf in Kürze verfügbare Möglichkeiten.
 

  • Literatur

  • 1 Onkopedia Leitlinie Multiples Myelom. www.onkopedia.com/de/onkopedia/guidelines/multiples-myelom
    PubMedGoogle Scholar
  • 2 Kyle RA, Larson DR, Therneau TM. et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2018; 378: 241-249
    CrossrefPubMedGoogle Scholar
  • 3 Braggio E, Kortum KM, Stewart AK. SnapShot: Multiple Myeloma. Cancer Cell 2015; 28: 678-678 e671
    CrossrefPubMedGoogle Scholar
  • 4 Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 2017; 17: 543-556
    CrossrefPubMedGoogle Scholar
  • 5 Palumbo A, Avet-Loiseau H, Oliva S. et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33: 2863-2869
    CrossrefPubMedGoogle Scholar
  • 6 Rajkumar SV, Dimopoulos MA, Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-548
    CrossrefPubMedGoogle Scholar
  • 7 Cavo M, Gay FM, Patriarca F. et al. Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02 / HO95 Study. Blood 2017; 130: 401-401
    PubMedGoogle Scholar
  • 8 Kumar S, Paiva B, Anderson KC. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328-e346
    CrossrefPubMedGoogle Scholar
  • 9 Kumar S, Kaufman JL, Gasparetto C. et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017; 130: 2401-2409
    CrossrefPubMedGoogle Scholar
  • 10 Mateos M-V, Martinez LopezJ, Rodriguez-Otero P. et al. Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. Blood 2017; 130: 402-402
    PubMedGoogle Scholar
  • 11 Hofmeister CC, Chari A, Cohen Y. et al. Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study. Blood 2017; 130: 510-510
    PubMedGoogle Scholar